Back to Peptide Pedia
Growth Hormone
Well Researched

CJC-1295 / Ipamorelin

CJC+IPA

Combined GHRH analog and selective secretagogue.

Also known as: CJC-1295 (no DAC) + Ipamorelin Protocol, Mod GRF + Ipamorelin

Research dose rangeCJC 100 mcg + Ipa 100–200 mcg per dose
Route studiedSubcutaneous
Study duration1–2× daily, multi-week studies
Storage2–8 °C reconstituted

Overview

This widely referenced research pairing combines CJC-1295 (no DAC), a GHRH analog, with Ipamorelin, a selective secretagogue, to study synergistic pulsatile GH release.

Key research findings

The most popular GH-axis research combination, pairing a GHRH analog (CJC-1295) with a selective GHRP (ipamorelin). The two act through complementary receptors to produce a larger, more physiologic GH pulse than either alone, while ipamorelin's selectivity keeps cortisol and prolactin minimal.

Mechanism of action

CJC-1295 stimulates GHRH receptors while Ipamorelin activates the ghrelin receptor, combining two complementary GH-release pathways.

Molecular information

WeightCombination (3,368 + 712 Da)
LengthTwo peptides (30 aa + 5 aa)
TypeGHRH analog + selective GHRP combination

Mod-GRF(1-29) without DAC combined with ipamorelin; often mixed in one research vial.

Pharmacokinetics

Peak: ~0.5 hoursHalf-life: ~0.5–2 hours (combined components)Cleared: ~8 hours
Peak · 1hHalf-life · 5h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

  • Synergistic GH-release research
  • Pulsatile-secretion studies
  • Body-composition investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Standard referenceAmount: 100 mcg CJC + 100–200 mcg IpaFrequency: 1–2× dailyRoute: Subcutaneous
Pre-sleep referenceAmount: 100 mcg + 200 mcgFrequency: Once nightlyRoute: Subcutaneous

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

  1. Acute (per dose)

    Amplified, pulsatile GH release reported within ~30 minutes of co-administration.

  2. Week 2–4

    Cumulative IGF-1 elevation reported with consistent dosing.

  3. Ongoing

    Pulsatile pattern preserved; effects taper after discontinuation.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

CJC-1295 (with DAC)

Redundant GHRH-receptor activation with the combo's CJC component.

Avoid combination

GHRP-6

Redundant GHRP activity with the ipamorelin component.

Avoid combination

MK-677

Additional GH/IGF-1 stimulation; monitor in research.

Use caution

BPC-157

No known interactions. Different mechanisms - GH optimization versus direct tissue repair signaling.

Compatible

HGH

Redundant mechanisms may cause excessive GH levels and suppress natural pulsatile release patterns.

Avoid combination

How to reconstitute

Important

Reconstitute with bacteriostatic water, swirl gently, and refrigerate. When pre-mixed, both peptides share the same handling requirements.

  1. 1Allow the vial(s) to reach room temperature (15���20 minutes).
  2. 2Swab the stopper with alcohol and let it air dry.
  3. 3Add bacteriostatic water slowly down the vial wall.
  4. 4Swirl gently until dissolved into a clear solution.
  5. 5Refrigerate at 2–8 °C and protect from light.
Open reconstitution calculator

Quality indicators

Uniform white powder

Lyophilized cake should be white to off-white without discoloration.

Clear solution

Reconstitutes to a clear, colorless, particle-free solution.

Cold-chain integrity

Reconstituted solution requires 2–8 °C storage.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

  • Generally well tolerated due to ipamorelin's selectivity; transient head-rush or injection-site reactions reported.
  • IGF-1 monitoring is standard in GH-axis research designs.

References & further reading

GHRH + GHRP synergy on GH secretion (review)

Human/preclinicalcombinationGH pulse

Review describing the synergistic GH release achieved by combining GHRH analogs with GH secretagogues.

View study

Topics

ghrhsecretagoguecombination

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level
Well Researched

Substantial peer-reviewed research across multiple models.

Quick reference
Dose rangeCJC 100 mcg + Ipa 100–200 mcg per dose
RouteSubcutaneous
Duration1–2× daily, multi-week studies
Storage2–8 °C reconstituted
Half-life~0.5–2 hours (combined components)
Available at Reviva

CJC-1295 / Ipamorelin is stocked as a research-grade compound, ≥99% by HPLC, third-party verified.

View in catalogue
Research toolsReconstitution calculator

Related compounds

CJC

CJC-1295 (No DAC)

Short-acting GHRH analog.

IPA

Ipamorelin

Selective growth-hormone secretagogue.

CJC-DAC

CJC-1295 with DAC

Long-acting GHRH analog with extended half-life.

SERM

Sermorelin

Foundational GHRH analog.